Type 2 Diabetes Pipeline Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | AstraZeneca, Novo Nordisk

 Breaking News
  • No posts were found

Type 2 Diabetes Pipeline Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | AstraZeneca, Novo Nordisk

June 12
10:00 2024
Type 2 Diabetes Pipeline Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | AstraZeneca, Novo Nordisk
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Type 2 Diabetes pipeline constitutes 100+ key companies continuously working towards developing 100+ Type 2 Diabetes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Type 2 Diabetes Pipeline report provides a thorough commercial and clinical evaluation of pipeline products, spanning from pre-clinical development to market availability. It includes a comprehensive overview of each drug, encompassing its mechanism of action, clinical studies, potential NDA approvals, and various product development aspects such as technology, collaborations, mergers, acquisitions, funding, designations, and other pertinent details.

 

Type 2 Diabetes Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Type 2 Diabetes Market.

 

Some of the key takeaways from the Type 2 Diabetes Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Type 2 Diabetes treatment therapies with a considerable amount of success over the years. 

  • Type 2 Diabetes companies working in the treatment market are Abarceo Pharma, Carmot Therapeutics, Neurodon, Eccogene, Suzhou Alphamab Co., Ltd., Sciwind Biosciences, Amgen, Regor Pharmaceuticals, Jiangsu Hengrui Medicine Co, Celon Pharma, Oramed Pharmaceuticals, Eli Lilly and Company, Novo Nordisk, and others, are developing therapies for the Type 2 Diabetes treatment 

  • Emerging Type 2 Diabetes therapies in the different phases of clinical trials are- Research programme-type 2 diabetes mellitus therapeutics, CT996, NRDN-101, ECC5004, KN056, XW014, AMG 133, RGT001-075, HR17031, CPL207280, ORMD-0801, LY-3209590, Insulin icodec, and others are expected to have a significant impact on the Type 2 Diabetes market in the coming years.   

  • In February 2024, Oramed Pharmaceuticals announced plans to restart a Phase III trial for its oral insulin candidate for type 2 diabetes (T2D) after the previous pivotal trial did not meet its endpoints. Following this setback, the company conducted a thorough review of the trial data for its oral insulin candidate ORMD-0801, which failed in a US trial in January 2023 (NCT04606576). The review identified subpopulations of patients, based on factors like body mass index (BMI), baseline hemoglobin A1C (HbA1c), and age, who responded well to the oral insulin, showing a statistically significant reduction in HbA1c.  

 

Type 2 Diabetes Overview

Type 2 diabetes is a chronic condition that affects the way the body processes blood sugar (glucose). It is characterized by insulin resistance and relative insulin deficiency, leading to elevated blood glucose levels. Unlike type 1 diabetes, which is an autoimmune condition where the body attacks insulin-producing cells, type 2 diabetes is often associated with lifestyle factors and genetic predisposition.

 

Get a Free Sample PDF Report to know more about Type 2 Diabetes Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/type-2-diabetes-pipeline-insight

 

Emerging Type 2 Diabetes Drugs Under Different Phases of Clinical Development Include:

  • ECC5004: Eccogene

  • KN056: Suzhou Alphamab Co., Ltd.

  • XW014: Sciwind Biosciences

  • AMG 133: Amgen

  • RGT001-075: Regor Pharmaceuticals

  • HR17031: Jiangsu Hengrui Medicine Co

  • CPL207280: Celon Pharma

  • Research programme: type 2 diabetes mellitus therapeutics: Abarceo Pharma

  • CT996: Carmot Therapeutics

  • NRDN-101: Neurodon

  • ORMD-0801: Oramed Pharmaceuticals

  • LY-3209590: Eli Lilly and Company

  • Insulin icodec: Novo Nordisk

 

Type 2 Diabetes Route of Administration

Type 2 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

  • Molecule Type

 

Type 2 Diabetes Molecule Type

Type 2 Diabetes Products have been categorized under various Molecule types, such as

  • Oligonucleotide

  • Peptide

  • Small molecule

  • Product Type

 

Type 2 Diabetes Pipeline Therapeutics Assessment

  • Type 2 Diabetes Assessment by Product Type

  • Type 2 Diabetes By Stage and Product Type

  • Type 2 Diabetes Assessment by Route of Administration

  • Type 2 Diabetes By Stage and Route of Administration

  • Type 2 Diabetes Assessment by Molecule Type

  • Type 2 Diabetes by Stage and Molecule Type

 

DelveInsight’s Type 2 Diabetes Report covers around 100+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Type 2 Diabetes product details are provided in the report. Download the Type 2 Diabetes pipeline report to learn more about the emerging Type 2 Diabetes therapies

 

Some of the key companies in the Type 2 Diabetes Therapeutics Market include:

Key companies developing therapies for Type 2 Diabetes are – Novo Nordisk, Jiangsu Hengrui Medicine, Melior Pharmaceuticals, Adocia, Pfizer, AgeX Therapeutics, CarmotTherapeutics, Genexine, Inc., OPKO Health, Inc., VitNovo, Inc., Sciwind Biosciences, Caelus Health, SCOHIA PHARMA, Ionis Pharmaceuticals, Eli Lilly and Company, Oramed Pharmaceuticals, AstraZeneca, Aerami Therapeutics, Viking Therapeutics, VTV Therapeutics, AptamiR Therapeutics, Avolynt, Inc., Suzhou Yabao Pharmaceutical, CONJUCHEM, LLC., Hua Medicine, REMD Biotherapeutics, Novmeta Pharma, Afimmune Limited,  Xeris Pharmaceuticals, Akros Pharma Inc., and others.

 

Type 2 Diabetes Pipeline Analysis:

The Type 2 Diabetes pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Type 2 Diabetes with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 2 Diabetes Treatment.

  • Type 2 Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Type 2 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 2 Diabetes market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Type 2 Diabetes drugs and therapies

 

Type 2 Diabetes Pipeline Market Drivers

  • Increasing Prevalence, government bodies are collaborating with major market players for the launch of new products, increase in the demand for insulin over the world are some of the important factors that are fueling the Type 2 Diabetes Market.

 

Type 2 Diabetes Pipeline Market Barriers

  • However, side-effects associated with the treatment of Type 2 Diabetes, a lack of knowledge about a healthy diet, medication initiation and other factors are creating obstacles in the Type 2 Diabetes Market growth.

 

Scope of Type 2 Diabetes Pipeline Drug Insight    

  • Coverage: Global

  • Key Type 2 Diabetes Companies: Abarceo Pharma, Carmot Therapeutics, Neurodon, Eccogene, Suzhou Alphamab Co., Ltd., Sciwind Biosciences, Amgen, Regor Pharmaceuticals, Jiangsu Hengrui Medicine Co, Celon Pharma, Oramed Pharmaceuticals, Eli Lilly and Company, Novo Nordisk, and others

  • Key Type 2 Diabetes Therapies: Research programme-type 2 diabetes mellitus therapeutics, CT996, NRDN-101, ECC5004, KN056, XW014, AMG 133, RGT001-075, HR17031, CPL207280, ORMD-0801, LY-3209590, Insulin icodec, and others

  • Type 2 Diabetes Therapeutic Assessment: Type 2 Diabetes current marketed and Type 2 Diabetes emerging therapies

  • Type 2 Diabetes Market Dynamics: Type 2 Diabetes market drivers and Type 2 Diabetes market barriers 

 

Request for Sample PDF Report for Type 2 Diabetes Pipeline Assessment and clinical trials

 

Table of Contents

1. Type 2 Diabetes Report Introduction

2. Type 2 Diabetes Executive Summary

3. Type 2 Diabetes Overview

4. Type 2 Diabetes- Analytical Perspective In-depth Commercial Assessment

5. Type 2 Diabetes Pipeline Therapeutics

6. Type 2 Diabetes Late Stage Products (Phase II/III)

7. Type 2 Diabetes Mid Stage Products (Phase II)

8. Type 2 Diabetes Early Stage Products (Phase I)

9. Type 2 Diabetes Preclinical Stage Products

10. Type 2 Diabetes Therapeutics Assessment

11. Type 2 Diabetes Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Type 2 Diabetes Key Companies

14. Type 2 Diabetes Key Products

15. Type 2 Diabetes Unmet Needs

16 . Type 2 Diabetes Market Drivers and Barriers

17. Type 2 Diabetes Future Perspectives and Conclusion

18. Type 2 Diabetes Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories